AQST Investors Have Opportunity to Lead Aquestive Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Aquestive Therapeutics, Inc. during the specified Class Period, highlighting potential securities fraud related to the company's New Drug Application for Anaphylm [1]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between June 16, 2025, and January 8, 2026, and claims that the defendants made false or misleading statements regarding the company's NDA for Anaphylm [1]. - The lawsuit alleges that Aquestive concealed significant human factors related to the use and deployment of its sublingual film, impacting investor decisions [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [1]. - The firm has a history of achieving significant settlements for investors, including over $438 million in 2019 alone [1]. - Investors interested in joining the class action can find more information through the provided contact details [1].